CorAssist

Company Overview

Snapshot

Founded in January 2003 by Yotam Reisner, Shay Dubi, and Yair Feld, CorAssist operated with 1-10 employees. The company raised $14.5 million across 4 funding rounds from 7 investors. In December 2022, CorAssist ceased to operate.

Business overview

CorAssist was a clinical-stage medical device company specializing in therapeutic products for heart failure with preserved ejection fraction. The company developed proprietary technology to improve cardiac diastolic function, primarily through its CORolla and ImCardia devices. CORolla was an elastic, self-expanding, internal, spring-like device implanted inside the left ventricle, while ImCardia was an elastic, self-expanding device attached to the external left ventricular surface. CorAssist operated within the Health Tech & Life Sciences sector, focusing on medical devices and medical treatment & therapeutics for patients and healthcare providers.

Company Intelligence Q&A

What was the final operational status of CorAssist?

CorAssist ceased to operate in December 2022.

When did CorAssist conduct its first human trial for the CORolla implant?

In August 2017, a Canadian man became the first person to receive CorAssist's CORolla implant to treat heart failure. The procedure was performed at Haifa's Rambam Medical Center, and the Health Ministry authorized up to 10 clinical trials for the device.

Which investors participated in CorAssist's March 2009 funding round?

In March 2009, CorAssist raised funding from investors including Aurum Ventures M.K.I.

When did CorAssist raise its Seed round of funding?

In January 2006, CorAssist raised a Seed funding round from investors including The Yozma Group.

When did CorAssist raise its Pre-Seed funding round?

In July 2004, CorAssist raised a Pre-Seed funding round from Israel HealthCare Ventures and The Yozma Group.